FDA approves first nasal-administered dental anesthetic: 5 key notes

The US Food and Drug Administration recently approved KOVANAZE, the first nasal-administered dental anesthetic.

Here are five key notes:

1. KOVANAZE is the first product developed by the Fort Collins, Colo.-based company St. Renatus.

2. Traditionally, the dental industry has used needle injected anesthetic. However, KOVANAZE is administered through a nasal spray, without the use of a needle.

3. KOVANAZE contains tetracaineHCl (an ester local anesthetic) and oxymetazolineHCl (a vasoconstrictor).

4. The nasal spray is a topical, tooth nerve anesthetic, developed for dental procedures involving the upper teeth.

5. St. Renatus specifies that the anesthetic is meant for restoratives procedures on Teeth 4 through 13 and A through J in adults and children who weigh more than 40 kilograms.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast